Coronary Intervention & Surgery

The prices of implantable medical devices to treat heart patients are up to six times higher in the United States than Germany, according to a study published Oct. 1 in Health Affairs.

Same-day discharge following elective percutaneous coronary intervention (PCI) was safe and resulted in more than $5,000 in savings per procedure, according to an analysis of operations performed from 2006 through 2015. Yet only 9.1 percent of interventions that were studied achieved same-day discharge, representing an opportunity to trim healthcare costs in the United States.

A press conference at the 2018 Transcatheter Cardiovascular Therapeutics meeting in San Diego on Tuesday, Sept. 25, morphed into a discussion about the future of bioresorbable vascular scaffolds (BVS) and whether it’s worth pursuing bioresorbable stent technology at all.

Acute coronary syndrome patients who were given a loading dose of atorvastatin before percutaneous coronary intervention (PCI) experienced a 28 percent reduction in major adverse cardiovascular events (MACE) over the following 30 days, according to a secondary analysis of the randomized SECURE-PCI trial published in JAMA Cardiology.

Cardiologists at Henry Ford Hospital in Detroit have successfully performed the country’s first implantation of the Neovasc Reducer—a stainless steel, hourglass-shaped heart mesh designed to alleviate difficult angina—the hospital announced in a statement Sept. 26.

With additional testing for nonobstructive coronary artery disease (CAD), researchers effectively diagnosed microvascular and/or vasospastic angina—as well as non-cardiac related chest pain—and used that information to guide therapy decisions and significantly improve angina and quality-of-life outcomes.

Intravascular ultrasound (IVUS)-guided stent implantation offers improved clinical outcomes for heart patients over a traditional angiography-guided approach, researchers from China reported at this week’s Transcatheter Cardiovascular Therapeutics (TCT) meeting in San Diego, California.

A novel, polymer-free amphilius-eluting stent known as the “Cre8” was proven noninferior to the latest-generation permanent polymer drug-eluting stent in the first large-scale trial of its kind, according to research presented at the Cardiovascular Research Foundation’s 30th annual TCT conference in San Diego.

SAN DIEGO — The ultra-thin Orsiro drug-eluting stent (DES) maintained superior outcomes at two years of follow-up in a head-to-head trial against Abbott’s Xience stent, according to results presented this weekend at Transcatheter Cardiovascular Therapeutics 2018 and published online in the Journal of the American College of Cardiology.

A strict protocol mandating coronary angiography and therapeutic hypothermia contributed to “startling” improvements in survival rates for out-of-hospital cardiac arrest (OHCA), researchers reported in JACC: Cardiovascular Interventions.

The proportion of percutaneous coronary interventions (PCIs) performed in nonagenarians has more than doubled in the last decade in the United States, offering a significant survival benefit for those deemed healthy enough for the procedure, according to a study published online Sept. 17 in JACC: Cardiovascular Interventions.

Off-pump coronary artery bypass grafting (CABG) is associated with an 11 percent increased risk of mortality compared to on-pump CABG, according to a registry study of cardiac surgeries performed in New Jersey from 2005 to 2011.